BioCentury
ARTICLE | Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

December 21, 2018 7:51 PM UTC

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) on Dec. 18 in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing to begin "formal" preclinical development of pulmonary arterial hypertension (PAH) compound MGX292. A Phase I trial is slated for 2021...

BCIQ Company Profiles

Morphogen-IX Ltd.